Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4812)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 14, 2023 (publication date) through Aug 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1614-1626 [PMID: 36970591 DOI: 10.3748/wjg.v29.i10.1614] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i10/1614.htm |
| Number | Citing Articles |
| 1 |
Jiayi Wu, Junyi Wu, Shuqun Li, Mengchao Luo, Zhenxin Zeng, Yinan Li, Yangkai Fu, Han Li, Deyi Liu, Xiangye Ou, Zhongtai Lin, Shaoming Wei, Maolin Yan. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics. BioScience Trends 2024; 18(1): 42 doi: 10.5582/bst.2023.01326
|
| 2 |
Lei Wang, Li Lin, Wei Zhou. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis. Pharmacology & Therapeutics 2024; 257: 108634 doi: 10.1016/j.pharmthera.2024.108634
|
| 3 |
Liyuan Hao, Shenghao Li, Fanghang Ye, Hengyi Wang, Yuxin Zhong, Xiaoyi Zhang, Xiaoyu Hu, Xiaopeng Huang. The current status and future of targeted-immune combination for hepatocellular carcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1418965
|
| 4 |
Jingwen Feng, Yi Zhao, Lin Zhai, Jingxu Zhou. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Medicine 2024; 103(18): e38037 doi: 10.1097/MD.0000000000038037
|
| 5 |
Jianfei Wu, Xuefeng Bai, Guodong Yu, Quan Zhang, Xixi Tian, Yuan Wang. Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2024; 150(7) doi: 10.1007/s00432-024-05854-8
|
| 6 |
Feng Han, Xiao-Han Wang, Chen-Zhou Xu. Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(7): 3308-3320 doi: 10.4251/wjgo.v16.i7.3308
|
| 7 |
Junning Liu, Song Wei, Linfeng Yang, Jiahui Yu, Duan Yan, Pengsheng Yi. Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology 2023; 149(15): 14451 doi: 10.1007/s00432-023-05231-x
|
| 8 |
Christina G. Dalzell, Amy C. Taylor, Sarah B. White. New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma. Cancers 2023; 15(24): 5749 doi: 10.3390/cancers15245749
|
| 9 |
YiFeng Liang, LiMing Gan, DeJin Zeng, LangHua Lin, ZheKun Xiong, FangLian Liao, ALing Wang. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. Clinical and Translational Oncology 2024; doi: 10.1007/s12094-024-03458-9
|
| 10 |
Xingzhi Li, Zhihong Tang, Qingqing Pang, Xiaobo Wang, Tao Bai, Jie Chen, Meng Wei, Tao Wei, Lequn Li, Feixiang Wu. The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD‑1 Inhibitors. Journal of Hepatocellular Carcinoma 2024; : 1641 doi: 10.2147/JHC.S481816
|
| 11 |
Hao Wang, Yuan Liang, Zheng Liu, Rui Zhang, Jiashuo Chao, Mingming Wang, Mu Liu, Lei Qiao, Zhengfeng Xuan, Haitao Zhao, Ling Lu. POSTN+cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 2024; 12(7): e008721 doi: 10.1136/jitc-2023-008721
|